Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
OX-1(Oxidien) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
OX-1(Oxidien): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
KC-1086 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
KC-1086: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Recombinant anti-human EGFR antibody/IL-10 bispecific FC fusion protein(Dingfu Biotarget) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Recombinant anti-human EGFR antibody/IL-10 bispecific FC fusion protein(Dingfu Biotarget): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical
9 min read
AMT-143 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
AMT-143: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Guselkumab in Arthritis, Psoriatic: NCT07141004 Clinical Landscape Report 2026
15 October 2026
NCT07141004 clinical landscape for Arthritis, Psoriatic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Disitamab Vedotin in Muscle Invasive Bladder Urothelial Carcinoma: NCT07142200 Clinical Landscape Report 2026
15 October 2026
NCT07142200 clinical landscape for Muscle Invasive Bladder Urothelial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
Fludarabine Phosphate in Scleroderma, Diffuse: NCT07144462 Clinical Landscape Report 2026
15 October 2026
NCT07144462 clinical landscape for Scleroderma, Diffuse: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Donor Derived CD117 CAR-T Cells(Yake Biotechnology) in Refractory acute myeloid leukemia: NCT07144020 Clinical Landscape Report 2026
15 October 2026
NCT07144020 clinical landscape for Refractory acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
SPY072 in Arthritis, Psoriatic: NCT07148414 Clinical Landscape Report 2026
15 October 2026
NCT07148414 clinical landscape for Arthritis, Psoriatic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
STR-P004 in Idiopathic Inflammatory Myopathies: NCT07143617 Clinical Landscape Report 2026
15 October 2026
NCT07143617 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Allogeneic Mesenchymal Stem Cell-Derived Exosome(Biocells Medical) in Multiple Sclerosis: NCT07146087 Clinical Landscape Report 2026
15 October 2026
NCT07146087 clinical landscape for Multiple Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
EVO-756 in Dermatitis, Atopic: NCT07150845 Clinical Landscape Report 2026
15 October 2026
NCT07150845 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.